drugset
drugset / Trial / NCT05647343

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

NCT05647343 ↗

Phase 1 Completed 42 enrolled Atlas Molecular Pharma
RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

Timeline

Start
2023-03-31
Primary completion
2024-04-08
Completion
2024-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciclopirox Unknown 0.2 mg/kg Oral
Subject Ciclopirox Unknown 0.5 mg/kg Oral
Subject Ciclopirox Unknown 1 mg/kg Oral
Subject Ciclopirox Unknown 2 mg/kg Oral
Subject Ciclopirox Unknown 4 mg/kg Oral

Indications

No indication recorded.